We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bayer Submits Application for Heart Failure Drug in China
Read MoreHide Full Article
Bayer AG (BAYRY - Free Report) announced it has submitted a regulatory application in China seeking approval for its investigational drug, vericiguat, to treat patients with symptomatic chronic heart failure with an ejection fraction (HFrEF) less than 45%, who have had a previous worsening heart failure event, in combination with available heart failure therapies. Vericiguat is being jointly developed with Merck and Co. (MRK - Free Report) .
Vericiguat is an investigational, oral, once-daily, direct stimulator of the soluble guanylate cyclase (sGC) enzyme.
Shares of the company have lost 19.1% so far this year against the industry’s 1.4% growth.
The new drug application (NDA) was submitted to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), which was based on positive Phase III data from the VICTORIA study. The VICTORIA study evaluated vericiguat versus placebo when given in combination with available heart failure therapies in patients with worsening chronic HFrEF.
In July, the FDA accepted for priority review the NDA for vericiguat. The FDA set an action date of Jan 20, 2021. The marketing authorization application (MAA) submitted to the European Medicines Agency (EMA) and the NDA to the Ministry of Health, Labor and Welfare (MHLW) in Japan were based on positive phase III data from the VICTORIA study.
About 13.7 million patients are living with heart failure in China. Despite huge progress made on addressing this disease, the cardiovascular event rates are high, creating a huge unmet need for new therapies to reduce the risk of death and hospitalizations.
Novartis’ (NVS - Free Report) Entresto is approved to treat HFrEF. Amgen (AMGN - Free Report) and partner Cytokinetics’s pipeline candidate,omecamtiv mecarbil, is in late-stage development for HFrEF. AstraZeneca’s SGLT2 inhibitor,Farxiga, is also being evaluated in two phase III studies for HFrEF and heart failure with preserved ejection fraction (HFpEF).
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Bayer Submits Application for Heart Failure Drug in China
Bayer AG (BAYRY - Free Report) announced it has submitted a regulatory application in China seeking approval for its investigational drug, vericiguat, to treat patients with symptomatic chronic heart failure with an ejection fraction (HFrEF) less than 45%, who have had a previous worsening heart failure event, in combination with available heart failure therapies. Vericiguat is being jointly developed with Merck and Co. (MRK - Free Report) .
Vericiguat is an investigational, oral, once-daily, direct stimulator of the soluble guanylate cyclase (sGC) enzyme.
Shares of the company have lost 19.1% so far this year against the industry’s 1.4% growth.
The new drug application (NDA) was submitted to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), which was based on positive Phase III data from the VICTORIA study. The VICTORIA study evaluated vericiguat versus placebo when given in combination with available heart failure therapies in patients with worsening chronic HFrEF.
In July, the FDA accepted for priority review the NDA for vericiguat. The FDA set an action date of Jan 20, 2021. The marketing authorization application (MAA) submitted to the European Medicines Agency (EMA) and the NDA to the Ministry of Health, Labor and Welfare (MHLW) in Japan were based on positive phase III data from the VICTORIA study.
About 13.7 million patients are living with heart failure in China. Despite huge progress made on addressing this disease, the cardiovascular event rates are high, creating a huge unmet need for new therapies to reduce the risk of death and hospitalizations.
Novartis’ (NVS - Free Report) Entresto is approved to treat HFrEF. Amgen (AMGN - Free Report) and partner Cytokinetics’s pipeline candidate,omecamtiv mecarbil, is in late-stage development for HFrEF. AstraZeneca’s SGLT2 inhibitor,Farxiga, is also being evaluated in two phase III studies for HFrEF and heart failure with preserved ejection fraction (HFpEF).
Bayer currently carries a Zacks Rank #4 (Sell).
Bayer Aktiengesellschaft Price
Bayer Aktiengesellschaft price | Bayer Aktiengesellschaft Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>